Table 3 Multivariate analysis for progression-free survival and overall survival, including the androgenic status in a model with the widely accepted prognostic factors in glioblastoma
From: Androgen deficiency is associated with a better prognosis in glioblastoma
Variable | Hazard ratio | 95% confidence interval | p-value | |
|---|---|---|---|---|
Lower | Upper | |||
Progression-free survival | ||||
Age | 1.070 | 1.01 | 1.13 | 0.016 |
Karnofsky < 70 | 0.000 | 0.00 | - | 0.983 |
Resection: subtotal vs. biopsy | 1.043 | 0.22 | 5.05 | 0.958 |
Resection: complete vs. biopsy | 0.617 | 0.18 | 2.08 | 0.435 |
MGMT methylation | 2.239 | 0.78 | 6.44 | 0.135 |
Normal androgenic status | 6.346 | 1.81 | 22.22 | 0.004 |
Overall survival | ||||
Age | 1.051 | 0.98 | 1.12 | 0.137 |
Karnofsky < 70 | 0.000 | 0.00 | − | 0.987 |
Resection: subtotal vs. biopsy | 0.288 | 0.03 | 2.38 | 0.248 |
Resection: complete vs. biopsy | 0.256 | 0.05 | 1.23 | 0.090 |
MGMT methylation | 2.008 | 0.56 | 7.15 | 0.282 |
Normal androgenic status | 5.188 | 1.20 | 22.46 | 0.028 |